ESPR FY 2020 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

FY 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$228M+53.4% YoY

Gross Profit

$225M98.9% margin

Operating Income

-$121M-53.3% margin

Net Income

-$144M-63.1% margin

EPS (Diluted)

$-6.05

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$99M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$353M

Total Liabilities

$449M

Stockholders' Equity

-$96M

Cash & Equivalents

$305M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$228M	$148M	+53.4%
Gross Profit	$225M	$148M	+51.8%
Operating Income	-$121M	-$93M	-30.4%
Net Income	-$144M	-$97M	-47.7%